Oncology

Thermo Fisher Scientific Collaborates with Owlstone Medical to Advance the Identification of Novel Biomarkers

SAN JOSE, Calif., Nov. 7, 2019 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, and Owlstone Medical, the global leader in Breath Biopsy for applications in early disease detection and precision medicine, have entered into a collaborative partnership to advance the early diagnosis of cancer and other …

Read More »

QIAGEN Expands Portfolio of Immuno-Oncology Assets for Future Companion Diagnostics and Biomarkers

Hilden, Germany, and Germantown, Maryland, November 5, 2019 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a series of agreements that expand its immuno-oncology assets for future commercialization of novel companion diagnostics for precision medicine in immuno-oncology, in particular based on the powerful next-generation sequencing (NGS) technology. The agreements …

Read More »

Seattle Genetics and BeiGene Enter Global License Agreement for Advanced Preclinical Cancer Candidate

BOTHELL, Wash. & BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq: SGEN) and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160) today announced that the companies have entered into a license agreement for an advanced preclinical product candidate for treating cancer. The agent utilizes a proprietary Seattle Genetics antibody-based technology and is expected …

Read More »

Takeda and MD Anderson Collaborate to Accelerate Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform

HOUSTON & OSAKA, Japan–(BUSINESS WIRE)–The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced an exclusive license agreement and research agreement to develop cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies, ‘armored’ with IL-15, for the treatment of B-cell malignancies and other …

Read More »

FDA Grants Orphan Drug Designation to Autolus’ AUTO1 for Treatment of Acute Lymphoblastic Leukemia

LONDON, Nov. 05, 2019 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced that the United States Food and Drug Administration (FDA) has granted AUTO1 orphan drug designation for treatment of acute lymphoblastic leukemia (ALL) patients. …

Read More »

Allogene and Notch Therapeutics Partner for Development of iPSC-Derived Allogeneic Therapies for Hematologic Cancer Indications

SOUTH SAN FRANCISCO, Calif. and TORONTO, Nov. 05, 2019 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, and Notch Therapeutics Inc., an immune cell therapy company creating universally compatible, allogeneic T cell therapies for …

Read More »

Sandoz Receives FDA Approval for Long-Acting Oncology Supportive Care Biosimilar Ziextenzo (pegfilgrastim-bmez)

Holzkirchen, Nov. 5, 2019 – Sandoz, a Novartis division and a global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its biosimilar ZiextenzoTM (pegfilgrastim-bmez). Sandoz biosimilar pegfilgrastim has been approved and marketed in Europe as Ziextenzo® (pegfilgrastim) since 2018.  Sandoz now intends to launch Ziextenzo in the …

Read More »

Halozyme’s PEGPH20 Fails to Meet Primary Endpoint in its Phase 3 Trial in Patients with Metastatic Pancreas Cancer

SAN DIEGO, Nov. 4, 2019 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the HALO-301 Phase 3 clinical study evaluating investigational new drug PEGPH20 as a first-line therapy for treatment of patients with metastatic pancreas cancer failed to reach the primary endpoint of overall survival. The treatment arm …

Read More »

AVEO Oncology Announces Regulatory Update for Tivozanib in Renal Cell Carcinoma

CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVEO Oncology (NASDAQ: AVEO) today provided a regulatory update following a meeting with the U.S. Food and Drug Administration (FDA) to discuss results from the August 2019 overall survival (OS) analysis of the TIVO-3 trial and the Company’s proposal to proceed with a New Drug Application (NDA) for …

Read More »

Brain Cancer Patients Display Appropriate Immune Responses and Decreasing Tumor Biomarkers in AIVITA Biomedical’s Phase 2 Trial

IRVINE, Calif. – October 24, 2019 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today updated data from its ongoing glioblastoma Phase 2 clinical trial investigating AIVITA’s platform immunotherapy targeting tumor-initiating cells. In approximately 80% of treated patients, sequential blood plasma biomarker analyses have identified …

Read More »